Matrix

Fentanyl, the active ingredient in Matrix, is an opioid analgesic presented as a transdermal patch for transdermal use. It treats chronic severe pain and cancer‑related pain in patients who require continuous opioid therapy.

GNH USA supplies Matrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Fentanyl acts on the mu‑opioid receptor pathway to provide analgesia for severe pain conditions.

Chronic severe pain: delivers continuous opioid analgesia for patients with persistent severe pain. Cancer pain: manages moderate to severe pain associated with malignancy. Severe nociceptive pain: offers around‑the‑clock pain control for opioid‑tolerant individuals.

Fentanyl transdermal patches may cause a range of adverse reactions.

Common Side Effects: - Nausea: upset stomach and urge to vomit. - Constipation: reduced bowel movements. - Dizziness: light‑headed feeling. - Somnolence: increased sleepiness. - Skin irritation: redness or itching at the application site. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Adrenal insufficiency: impaired cortisol production. - Severe skin reactions: blistering or necrosis. - Opioid dependence or overdose: risk of addiction and life‑threatening toxicity.

When prescribing Matrix, clinicians should consider several safety measures.

Assess opioid tolerance: ensure patient is already opioid‑experienced before initiating therapy. Monitor respiratory status: watch for signs of depression, especially during dose changes. Evaluate contraindications: avoid use in acute respiratory disease, severe asthma, or uncontrolled hypoxia. Avoid concomitant MAO inhibitors: risk of severe opioid toxicity. Store at room temperature: keep patches in original pouch, protect from heat, moisture and light.

Fentanyl may interact with other medications, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): increased risk of respiratory depression. - MAO inhibitors: potential for severe opioid toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevated fentanyl plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced fentanyl efficacy. - Alcohol: additive sedation and respiratory effects. - Other opioids: cumulative opioid effect may require dose adjustment.